The FDA has approved Uplizna for generalized myasthenia gravis in adults who are anti-AChR and anti-MuSK antibody positive.

Amgen receives US FDA approval for Uplizna to treat Adults with generalized myasthenia gravis: Thousand Oaks, California Saturday, December 13, 2025, 11:00 Hrs [IST] Amgen announc ...

Minimally invasive treatment and earlier surgical consideration for thymectomy led the way as potential treatments for patients with ocular myasthenia gravis (OMG) in a new investigation, due to ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved UPLIZNA® (inebilizumab-cdon) for the treatment of generalized myasthenia gravis (gMG) in adults who ...

The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to ...

“Temporary loss of vision in one eye for seconds or minutes, as if a curtain was pulled down, is known as amaurosis fugax and ...

Amgen secures FDA approval for Uplinza in generalized myasthenia gravis, giving antibody-positive adults a targeted treatment option supported by Phase 3 data.

Kyverna Therapeutics stock upgraded to Strong Buy after positive phase 2 results for miv-cel in SPS and MG. Read the latest ...

A data monitoring committee recommended stopping the phase 3 trials of efgartigimod in thyroid eye disease due to lack of efficacy.

Immunovant shifts primary focus to IMVT-1402, a next-generation anti-FcRn, targeting Graves' Disease with potential ...